Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Drilling at Pt. Leamington unveils a copper-rich extension, targeting near-surface high-grade zones (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.


NDAQ:AUPH - Post by User

Aurinia Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
  • TimeScapeX
Comment by TimeScapeon Oct 26, 2021 12:51am
183 Views
Post# 34048217

RE:RE:Buyout?

RE:RE:Buyout?The AUPH stock price was $22 before the rumour came out on Friday.  A 50% premium would get get it to $33.  I doubt an offer would be for much more than that.  Maybe $35.  AUPH hasn't got much of a pipeline.  The lupus nephritis indication is excellent, and they should get a big market share, but it's not a huge market.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities